Parasite In The Payroll

A record Cyclospora year turns cafeteria lunches and catered shifts into contested workers’ compensation claims.

Sick Buildings, Compensable Claims

New York's Legionnaires' outbreak signals rising occupational-disease exposure for New York and New Jersey employers.

Long COVID's Dopamine Trail

For years, workers disabled by long COVID have described brain fog, memory loss, apathy, and slowed thinking that employers and carriers dismissed as subjective or unrelated to the job. A new study published in eBioMedicine (a Lancet-family journal) supplies something these claims have historically lacked: an objective, measurable brain signature of the injury. For the workers' compensation bar, that shift from symptom description to biological proof is the story.

What the study found

Researchers at the Brain Health Imaging Centre and the University of Toronto used PET imaging to measure vesicular monoamine transporter 2 (VMAT2), an accepted index of dopamine-releasing neuron density, in the striatum — the brain region governing motivation, movement, and memory. Comparing 24 adults who had long COVID with persistent neuropsychiatric symptoms against 24 age-matched healthy controls, the team found VMAT2 binding was 16% to 20% lower across three striatal regions in the long COVID group.

Crucially, the reductions tracked symptom severity. Lower binding in the ventral striatum correlated with apathy; in the dorsal putamen with motor slowing; and in the dorsal caudate with memory decline. Roughly a quarter of the variance in those symptoms was associated with the measured neuron loss. The authors interpret the pattern as reduced dopaminergic terminal integrity — loss of dopamine nerve terminals — comparable in magnitude to mild-to-moderate Parkinson's disease.

The researchers are careful about limits: the sample is small, participants were selected for significant neuropsychiatric symptoms, and an imaging correlation cannot by itself prove causation. An accompanying commentary notes the changes may not be permanent and calls for longitudinal follow-up. Those caveats matter — but they do not erase the significance of a reproducible, objective marker where none existed before.

Why this matters for workers' compensation

Long COVID claims have always turned on two hard questions: Did the job cause it, and how disabling is it? This research speaks directly to both.

●      Objective medical evidence. New Jersey — like most jurisdictions — requires more than a claimant's subjective complaints to establish a psychiatric or neurologic occupational disease. A biomarker of neuronal injury is precisely the kind of objective corroboration adjudicators look for.

●      Causation and permanency. Evidence that long COVID produces a Parkinson's-comparable loss of dopamine neurons strengthens arguments that resulting apathy, cognitive slowing, and memory deficits are organic sequelae of the infection — not pre-existing or purely psychological — and may support findings of lasting, ratable disability.

●      The occupational-disease framework. Under N.J.S.A. 34:15-31, a compensable occupational disease must be due in a material degree to conditions characteristic of or peculiar to the employment. For essential and frontline workers exposed on the job, biological proof of injury bolsters the nexus between workplace exposure and a measurable, disabling condition.

●      Rebutting the “ordinary disease of life” defense. Carriers routinely argue COVID is a common community illness, not an occupational hazard. Documented, lasting neurological injury reframes the dispute — the issue becomes the demonstrable sequelae of a workplace exposure, not merely where a common virus was contracted.

●      A treatment and mitigation angle. The authors suggest dopamine-augmenting therapies as a research direction. If effective treatments emerge, expect disputes over reasonable and necessary medical care, and over whether symptoms are permanent or amenable to mitigation.

None of this converts a difficult claim into an easy one. Imaging shows association, not causation, and defense experts will press the study's small sample and selection criteria. But the terrain has moved: petitioners can now point to a peer-reviewed, objective neurological substrate for symptoms that were long treated as unprovable.

The New Jersey proof standard

New Jersey courts have long demanded objective medical proof for occupational claims involving the mind and nervous system. In Goyden v. State Judiciary, 256 N.J. Super. 438 (App. Div. 1991), aff'd, 128 N.J. 54 (1992), the Appellate Division required objective evidence of workplace conditions sufficient to contribute to a psychiatric disability — not the claimant's say-so alone. In Brunell v. Wildwood Crest Police Dept., 176 N.J. 225 (2003), the Supreme Court elaborated on the “characteristic of or peculiar to” requirement for occupational disease. And in Magaw v. Middletown Bd. of Educ., 323 N.J. Super. 1 (App. Div. 1999), the court accepted a well-founded medical nexus between disease and workplace where supported by sufficient objective evidence. A validated brain-imaging biomarker fits squarely within the kind of proof these decisions contemplate.

The takeaway

This is early science, not settled law — and practitioners should present it with appropriate candor about its limits. Still, it marks a turning point. For the first time, the invisible, dismissed symptoms at the center of long COVID disability claims have a visible, measurable correlate in the brain. Attorneys, carriers, employers, and adjudicators should watch this line of research closely; it may become a recurring feature of medical proofs in the next generation of long COVID compensation litigation.

Sources

Liu YK, Persaud D, Vieira EL, et al. Loss of vesicular monoamine transporter 2 in striatum of long COVID and relationship to neuropsychiatric symptoms. eBioMedicine (2026). https://doi.org/10.1016/j.ebiom.2026.106339

Bergeson L. New study offers clues about long COVID's brain symptoms. CIDRAP, University of Minnesota (2026).

Guedj E, Beckman D. Accompanying commentary. eBioMedicine (2026).

Goyden v. State Judiciary, 256 N.J. Super. 438 (App. Div. 1991), aff'd, 128 N.J. 54 (1992).

Brunell v. Wildwood Crest Police Dept., 176 N.J. 225 (2003).

Magaw v. Middletown Bd. of Educ., 323 N.J. Super. 1 (App. Div. 1999).

N.J.S.A. 34:15-31 (compensable occupational disease); N.J.S.A. 34:15-36 (proof of disability).

About the Author

Jon L. Gelman of Wayne, NJ, is the author of NJ Workers' Compensation Law (West-Thomson-Reuters) and co-author of the national treatise Modern Workers' Compensation Law (West-Thomson-Reuters).

Blog: Workers' Compensation

LinkedIn: JonGelman

LinkedIn Group: Injured Workers Law & Advocacy Group

Author: Workers' Compensation Law West-Thomson-Reuters

Blue Sky: jongelman@bsky.social

Substack: jongelman.substack.com

© 2026 Jon L. Gelman. All rights reserved.

Attorney Advertising

Prior results do not guarantee a similar outcome.

Disclaimer   |   Download Adobe Reader

Virus on Board: Are We Ready?

Hantavirus, the Andes Strain, and the Workers' Compensation System's Preparedness for Person-to-Person Infectious Disease Outbreaks

Flu Season's Hidden Workers' Compensation Cost

As healthcare facilities across the nation report surging respiratory illness cases, the spotlight has turned once again to protecting those on the front lines of medicine. Recent surveillance data reveal a troubling trend: flu activity is increasing rapidly across the United States, with cases and hospitalizations rising by 78% and 53% respectively, in some states, while emergency department visits for influenza have more than doubled in certain regions.

Protecting Healthcare Heroes: Pandemic Preparedness

The 2025 Global Preparedness Monitoring Board (GPMB) report, The New Face of Pandemic Preparedness, arrives with a sobering message: five years after COVID-19 began, the world remains dangerously unprepared for the next pandemic. But perhaps nowhere is this vulnerability more acute than among healthcare workers and first responders—the very people we depend on when crisis strikes.

The Evolving Threat: Modernizing Biosafety to Prevent a Pandemic

Nearly a decade and a half after the initial discussion on the accidental release of potential pandemic pathogens (PPPs), the topic remains a critical concern. As research continues on highly pathogenic viruses like avian influenza A(H5N1), a healthy dose of anxiety and a strong commitment to safety are more important than ever. The debate around the risk-benefit of such research, once highlighted by experts like Marc Lipsitch and Barry R. Bloom, is ongoing, with current research showing a non-negligible risk that an accidental escape event would not be contained.

Is Workers' Compensation Ready? Pandemic Peril

Analyzing the preparedness of the U.S. workers' compensation system for a future pandemic requires considering multiple complex factors, including past administrative actions, potential policy shifts, and public health discourse. 

CDC Disruption: Workplace Health at Risk

The recent disruption of the US Centers for Disease Control and Prevention (CDC)'s activities has raised concerns about the potential negative impacts on public health, particularly regarding the identification and treatment of infectious diseases and occupational exposures. Here's how this disruption could negatively impact employees, employers, and ultimately increase the cost of workers' compensation claims:

Bird Flu: Is Human-to-Human Spread Taking Flight?

The Centers for Disease Control and Prevention [CDC] alert from September 27, 2024, raises concerns about human-to-human transmission of bird flu among workers. If this occurs, it will create a major occupational disease outbreak in the workplace that may severely impact workers’ compensation claims.

Bird Flu Strikes Colorado Poultry Workers: CDC Confirms

The US Centers for Disease Control [CDC]] has reported additional humans have been infected with bird flu.

Another Class of Benefits Proposed for Workers’ Compensation

The NJ Legislature is considering expanding the multitiered program to compensate the victims of industrial illness. This time a supplemental benefit program is being offered to compensate healthcare workers who contracted COVID-19.

NJ Workers at Risk Now for West Nile Virus

New Jersey workers again are now at risk for West Nile Virus. The warnings of the mosquito-borne illness are an alert for New Jersey workers to take adequate precautions against this infectious disease.The New Jersey Department of Health has confirmed the state’s first human cases of West Nile Virus (WNV) this year.

Monkeypox in the Workplace

Monkeypox is not merely a sexual or geographic disease it is an infectious disease that can cause many workers to be exposed. It is a contagious disease that is transmitted by body contact. Infectious diseases are compensable under most workers’ compensation acts.

Back to Work is Going to be Back to COVID

The US Centers for Disease Control [CDC] announced today a continuation of its flawed strategy to reduce the plateaued high transmission rates of COVID throughout the US. As workers return from summer vacation, COVID transmission will remain very high, and the workforce will be subject to primary and repeat COVID infections.

Is the Workers' Compensation System Prepared for Omicron (Updated 12/10/21)

As this holiday season approaches, employers, insurance companies, and employees will be facing what may be the biggest COVID challenges of the year. The highly infectious disease variant Omicron detected initially in South Africa is spreading worldwide, including reported cases in the US.

COVID-19: A lesson for the workers’ compensation industry

Michael Lewis’s new book, The Premonition, is about three characters and their struggle to alert the Nation about the COVID-19 pandemic. The book offers a shocking insight into the mismanagement of the public health care system. The workers’ compensation industry lacked adequate information to prepare for the epidemic properly. It must address this deficiency in the future.

Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials

-100% protection against severe disease
-Final analysis in U.K. trial confirms 96% efficacy against original strain of COVID-19
-Efficacy against variants confirmed in U.K. and South Africa

Searching for Vaccine in NJ

NJ Commissioner of Health Judith Persichilli COVID-19 provided a status report yesterday on the status of vaccine distribution in NJ. 

Testing Can’t Promise You a Rose Garden. But What Can It Promise?

Developing a pandemic preparedness strategy for the workplace is critical in control of COVID-19. Today's guest author, Michael Gelman, MD PhD, discusses the how the application of the latest medical information can achieve that goal.

The events of the past week have made it very clear:

Michael A Gelman MD PhD

there is no testing strategy that, alone, can guarantee safety from COVID-19. Rather, a strategy of targeted layered containment represents the best hope for reducing the risk of transmission. Even with the best testing achievable, masks help; distancing helps; being outdoors helps; reducing mass gatherings definitely helps; and in extremis, closing in-person schools and non-essential businesses helps. That’s why Governor Cuomo’s cluster action initiative, as advised by multiple nationally-recognized epidemiologists, is being implemented. It’s uncomfortable and onerous - but the shutdown in March and April was uncomfortable and onerous, and until there’s a lot more immunity than there is now, it’s the best we can do.